James Waldron

SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven's Kv7 ion channel activator on its way to market.

Just two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.

The month of September 2025 marked a low point for relations between the U.K. government and Big Pharma.

ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA (siRNA) medicines.

Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that analysts had once tipped as a potential blockbuster.

Roivant's $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.

Pharvaris' deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema (HAE) patients as the Swiss biotech awaits an FDA approval decision.

Evommune's G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial , wiping out the biotech's last hopes of developing the therapy for any itch-related conditions.

Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.